Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253083 | 0.97 | CYP1A2 (0.51) | CYP1A2CYP3A4GAACYP2C19EPHX2 | |
| SCHEMBL2380798 | 0.93 | CYP1A2 (0.54) | CYP1A2CYP3A4GAACYP2C19EPHX2 | |
| SCHEMBL12253089 | 0.92 | CYP1A2 (0.55) | CYP1A2CYP3A4GAACYP2C19EPHX2 | |
| SCHEMBL2380739 | 0.89 | LMNA (0.52) | MEN1KMT2ATBXA2RALDH1A1 | |
| SCHEMBL12253174 | 0.87 | KMT2A (0.51) | GAAEPHX2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2379471 | 0.87 | EPHX2 (0.48) | EPHX2EPHX1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12253064 | 0.86 | KMT2A (0.50) | CYP1A2CYP3A4GAACYP2C19EPHX2 | |
| SCHEMBL2380877 | 0.86 | TBXA2R (0.44) | EPHX2MEN1KMT2ASMN1; SMN2TBXA2R | |
| SCHEMBL12253103 | 0.86 | KMT2A (0.46) | EPHX2MEN1KMT2ASMN1; SMN2TBXA2R | |
| SCHEMBL2380187 | 0.86 | TBXA2R (0.55) | EPHX2MEN1KMT2ASMN1; SMN2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2547655-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CYP1A2 3535/4885CYP3A4 3259/4885GAA 2694/4885 |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CYP1A2 3535/4885CYP3A4 3259/4885GAA 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.